Multifactorial resistance to aminopeptidase inhibitor prodrug CHR2863 in myeloid leukemia cells: down-regulation of carboxylesterase 1, drug sequestration in lipid droplets and pro-survival activation ERK/Akt/mTOR

Aminopeptidase inhibitors are receiving attention as combination chemotherapeutic agents for the treatment of refractory acute myeloid leukemia. However, the factors determining therapeutic efficacy remain elusive. Here we identified the molecular basis of acquired resistance to CHR2863, an orally a...

Descripción completa

Detalles Bibliográficos
Autores principales: Verbrugge, Sue Ellen, Al, Marjon, Assaraf, Yehuda G., Kammerer, Sarah, Chandrupatla, Durga M.S.H., Honeywell, Richard, Musters, Rene P.J., Giovannetti, Elisa, O'Toole, Tom, Scheffer, George L., Krige, David, de Gruijl, Tanja D., Niessen, Hans W.M., Lems, Willem F., Kramer, Pieternella A., Scheper, Rik J., Cloos, Jacqueline, Ossenkoppele, Gert J., Peters, Godefridus J., Jansen, Gerrit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4868683/
https://www.ncbi.nlm.nih.gov/pubmed/26496029
http://dx.doi.org/10.18632/oncotarget.6169

Ejemplares similares

Ejemplares similares